Philippine Health Research Registry
Display Options
Results List
Results 1 - 9 of 9 research(es) under NUHRA Regime 2017 - 2022, Global competitiveness and innovation in health, Drug discovery and development

Show: All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

#
Study
         
Project Status:
Ongoing
Project Description:
This study uses a randomized, multicenter, double-blind, placebo-controlled parallel-group study design in which QAW039 or placebo is added to incoming SoC asthma therapy (Figure 3-1).  Asthma patients who are already receiving ICS or ICS with one asthma controller medication (see inclusion criterion 4 for allowed ICS doses and combinations) are t... [read more]
Project Status:
Ongoing
Project Description:
This study uses a single-cohort, 3-treatment arm, randomized (2:3:3 [140 mg: 70 mg: placebo]), double-blind study design in adult patients with episodic migraine. . A screening period of 2 weeks will be used to assess initial eligibility, followed by a 4-week baseline period (the maximum duration for the baseline period is 35 days), during which di... [read more]
Project Status:
Ongoing
Project Description:
This is a randomized, double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study. Subjects with T2DM >=10 and =6.5% to <=10.5%) and who meet 1 of the criteria below will be eligible to be screened: 1.  Are on diet and exercise for at least 8 weeks prior to screening or 2. Are on diet and exercise and a stable dose of metformi... [read more]
Project Status:
Ongoing
Project Description:
SHP640-301 is a phase III, global, multi-center, randomized, double-masked, parallel group, placebo controlled study designed to demonstrate the safety and efficacy of SHP640 ophthalmic suspension compared to PVP-I 0.6% ophthalmic solution and to placebo in treating adenoviral conjunctivitis.   SHP640, a novel topical ophthalmic suspension, is cur... [read more]
Project Status:
Ongoing
Project Description:
SHP640-303 is a phase III, global, multicenter, randomized, double-masked, parallel-group, placebocontrolled study designed to demonstrate the safety and efficacy of SHP640 ophthalmic suspension compared to placebo in treating bacterial conjunctivitis. In addition, an exploratory arm of PVP-I 0.6% ophthalmic solution will be included. SHP640, a nov... [read more]
Project Status:
Pending
Project Description:
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC] CRT) in patients with locally advanced, unresectable NSCLC (Stage III). Approximately 390 patients with locally advanced... [read more]
Project Status:
Pending
Project Description:
A Phase II randomised, controlled, open-label, early bactericidal activity trial
Project Status:
Pending
Project Description:
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with 6 cycles of standard of care chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy i... [read more]
Project Status:
Pending
Project Description:
This study is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo as consolidation therapy in patients with locally advanced, unresectable NSCLC (Stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy. Approximatel... [read more]